Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508117 · ClinicalTrials.gov registry record · Phase 2
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
A Phase 2 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01508117 is a Phase 2 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 1 participants.
The verdict
NCT01508117, a Phase 2 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.
Interventions
- RADIATION Radiation Therapy
- DRUG Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508117
The ClinicalTrials.gov registry entry for NCT01508117 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT01508117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508117 about?
NCT01508117 is a clinical study titled "Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients". The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.
What is the current status of trial NCT01508117?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2011-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01508117?
The interventions under investigation include: Radiation Therapy (RADIATION), Axitinib (DRUG).
Who is sponsoring clinical trial NCT01508117?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.